What Are the Effects of Abnormalities in the ALK Gene


[1] Schlessinger J. Cell signaling by receptor tyrosine kinases [J]. Cell, 2000, 141(7): 1117.

[2] Morris S W, Kirstein M N, Valentine M B, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma [J]. Science, 1994,263(5151): 1281-1284.

[3] Li R, Morris S W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy [J]. Medicinal Research Reviews, 2010, 28(3): 372-412.

[4] Stoica G E, Kuo A, Powers C, et al. Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types [J]. Journal of Biological Chemistry, 2002, 277(39): 35990-35998.

[5] Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene [J]. Cancer research, 2010, 70(23): 9827-9836.

[6] Bunting S F, Nussenzweig A. End-joining, translocations and cancer [J]. Nature Reviews Cancer, 2013, 13(7): 443-54.

[7] Bridge J A, Kanamori M, Ma Z, et al. Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor [J]. American Journal of Pathology, 2001, 159(2): 411-415.

[8] Soda M, Choi Y L, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J]. NATURE, 2007, 448(7153): 561-566.

[9] Kwak E L, Bang Y J, Camidge D R, et al. Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer [J]. New England Journal of Medicine, 2010, 363(18): 1693-1703.

[10] Lin E, Li L, Guan Y, et al. Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers [J]. Molecular Cancer Research, 2009, 7(9): 1466-1476.

[11] Kelly L M, Barila G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer [J]. Proceedings of the National Academy of Sciences, 2014, 111(11): 4233-4238.

[12] Osajima-Hakomori Y, Miyake I, Ohira M, et al. Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma [J]. American Journal of Pathology, 2005, 167(1): 0-222.

[13] Salido M, Pijuan L, Martínez-Avilés L, et al. Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer [J]. Journal of Thoracic Oncology, 2011, 6(1): 21-27.

[14] Rusthoven C G, Doebele R C. Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer [J]. Journal of Clinical Oncology, 2016: JCO.2016.67.2410.

[15] Minca E C, Portier B P, Wang Z, et al. ALK Status Testing in Non-Small Cell Lung Carcinoma [J]. The Journal of Molecular Diagnostics, 2013, 15(3): 341-346.

[16] Friboulet L, Li N, Katayama R, et al. The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer [J]. Cancer Discovery, 2014, 4(6): 662-673.

[17] Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance [J]. Cancer Letters, 2014, 351(2): 215-221.

[18] Drilon A, Siena S, Ou S H I, et al. Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1) [J]. Cancer Discovery, 2017, 7(4): CD-16-1237.

[19]Sang J, Acquaviva J, Friedland J C, et al. Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer [J]. Cancer Discovery, 2013, 3(4): 430-443.

[20] Doebele R C, Pilling A B, Aisner D L, et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer [J]. Clinical Cancer Research, 2014, 15(2): 133-135.

[21] Kim H R, Kim W S, Choi Y J, et al. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation [J]. Molecular Oncology, 2013, 7(6): 1093-1102.

[22] Katayama R, Sakashita T, Yanagitani N, et al. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer [J]. EBioMedicine, 2015, 3(C): 54-66.

[23] Remon J, Besse B. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer [J]. Current Opinion in Oncology, 2017, 29(2): 1.

Cite this article

CUSABIO team. What Are the Effects of Abnormalities in the ALK Gene. https://www.cusabio.com/c-20917.html


Leave a Comment

Your email address will not be published. Required fields are marked *
*CAPTCHA verification
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1